Understand the source comparison
Best Peptides for Celiac Disease: Comparison
Before reviewing specific peptides, understand that this comparison evaluates research-grade compounds based on preclinical evidence and proposed mechanisms—not clinical trial outcomes in celiac patients. None of these peptides are FDA-approved for celiac dise
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before reviewing specific peptides, understand that this comparison evaluates research-grade compounds based on preclinical evidence and proposed mechanisms—not clinical trial outcomes in celiac patients. None of these peptides are FDA-approved for celiac disease treatment.
- KPV 5MG
- NF-κB inhibition, reducing pro-inflammatory cytokine transcription in enterocytes
- Preclinical (murine colitis models)
- 5–20mg/kg IP in animal studies; oral bioavailability poor in humans
- No human trials; rapid peptidase degradation in GI tract limits oral efficacy
- Most direct anti-inflammatory mechanism for intestinal tissue; requires parenteral delivery to bypass degradation
- BPC-157
- VEGF upregulation, angiogenesis, collagen deposition for villous regeneration
- Preclinical (rat GI injury models)
- 10μg/kg daily in wound healing studies
- Zero clinical trials in celiac disease; mechanism extrapolated from IBD research
- Strongest evidence for structural tissue repair; addresses villous atrophy not immune dysregulation
- Thymosin Alpha-1
- Treg modulation, IL-2 receptor expression enhancement
- Clinical trials in autoimmune conditions (not celiac-specific)
- 1.6mg subcutaneous twice weekly in hepatitis trials
- Indirect mechanism—supports immune tolerance but doesn't repair gut barrier
- Addresses immune regulation upstream; relevant for patients with persistent gliadin antibodies despite GF diet
- Thymalin
- Thymic peptide complex; broad immunomodulatory effects
- Limited preclinical data
- Variable; typically 5–10mg in research contexts
- Poorly characterized; less specific than TA-1
- Less evidence than thymosin alpha-1; mechanism overlaps but specificity unclear
- Collagen Peptides (oral)
- Provides proline/glycine for tissue repair; minimal direct mechanism
- Consumer-grade evidence; no celiac-specific research
- 10–20g daily in commercial products
- Generic building blocks—not targeted therapy; marketing exceeds evidence
- Not comparable to research peptides; included for distinction from marketed 'gut healing' supplements